A comparative study of the adjuvanticity of Hansenula polymorpha, Saccharomyces cerevsiae and Yarrowia lipolytica in oral and nasal immunization with virus capsid antigens

Biotechnology Letters

Volumn 35, Issue 11, 2013, Pages 1881-1888

  Lee, Jae Young ^a   Xu, Mei Ling ^a   Kim, Hyoung Jin ^a   Kang, Hyun Ah ^a   Kim, Hong Jin ^a  

^a Chung Ang University   (South Korea)

Author keywords

Hansenula polymorpha; Influenza virus; Mucosal immunization; Papillomavirus; Virus like particles

Indexed keywords

HANSENULA POLYMORPHA; INFLUENZA VIRUS; MUCOSAL IMMUNIZATION; PAPILLOMAVIRUS; VIRUS-LIKE PARTICLES;

ANTIGENS; IMMUNIZATION; MAMMALS; YEAST;

VIRUSES;

FELINE IMMUNODEFICIENCY VIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; INFLUENZA A VIRUS; INFLUENZAVIRUS A; MIRIDAE; MUS; ORTHOMYXOVIRIDAE; PAPILLOMAVIRIDAE; PICHIA ANGUSTA; SACCHAROMYCES; YARROWIA LIPOLYTICA;

CAPSID PROTEIN; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; VIRUS ANTIGEN;

ANIMAL; ARTICLE; BLOOD; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOLOGY; INFLUENZA VIRUS A; INTRANASAL DRUG ADMINISTRATION; MOUSE; ORAL DRUG ADMINISTRATION; ORTHOMYXOVIRUS INFECTION; PICHIA; SACCHAROMYCES CEREVISIAE; SERUM; SURVIVAL; YARROWIA;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CAPSID PROTEINS; HUMAN PAPILLOMAVIRUS 16; IMMUNOGLOBULIN G; INFLUENZA A VIRUS; MICE; ORTHOMYXOVIRIDAE INFECTIONS; PICHIA; SACCHAROMYCES CEREVISIAE; SERUM; SURVIVAL ANALYSIS; YARROWIA;

EID: 84885605553     PISSN: 01415492     EISSN: 15736776     Source Type: Journal    
DOI: 10.1007/s10529-013-1273-8     Document Type: Article

References (25)

1. Celik E, Calik P (2012) Production of recombinant proteins by yeast cells. Biotechnol Adv 30: 1108-1118.
2. DeVane L (2004) Principles of pharmacokinetics and pharmacodynamics. In: Schartzberg AF, Nemeroff CB (eds) The American Psychiatric Publishing Text-book of Psychopharmacology, 3rd edn. American Psychiatric Pub, Washington, DC, pp 181-200.
3. Food and Drug Administration US (2001) Partial list of microorganisms and microbial-derived ingredients that are used in foods. http://wwwfdagov/Food/FoodIngredientsPackaging/ucm078956htm.
4. Frech SA, Dupont HL, Bourgeois AL, McKenzie R, Belkind-Gerson J, Figueroa JF, Okhuysen PC, Guerrero NH, Martinez-Sandoval FG, Melendez-Romero JH, Jiang ZD, Asturias EJ, Halpern J, Torres OR, Hoffman AS, Villar CP, Kassem RN, Flyer DC, Andersen BH, Kazempour K, Breisch SA, Glenn GM (2008) Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial. Lancet 371: 2019-2025.
5. Kim HJ, Kim SY, Lim SJ, Kim JY, Lee SJ (2010) One-step chromatographic purification of human papillomavirus type 16 L1 protein from Saccharomyces cerevisiae. Protein Expr Purif 70: 68-74.
6. Kim HJ, Lim SJ, Kwag HL (2012) The choice of resin-bound ligand affects the structure and immunogenicity of column-purified human papillomavirus type 16 virus-like particles. PLoS ONE 7: e35893.
7. Kushnir N, Streatfield SJ, Yusibov V (2012) Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development. Vaccine 31: 58-83.
8. Matsuura Y, Tohya Y, Mochizuki M, Takase K, Sugimura T (2001) Identification of conformational neutralizing epitopes on the capsid protein of canine calicivirus. J Gen Virol 82: 1695-1702.
9. McKenzie R, Bourgeois AL, Frech SA, Flyer DC, Bloom A, Kazempour K, Glenn GM (2007) Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebo-controlled challenge study. Vaccine 25: 3684-3691.
10. Mestecky J, Russell MW, Elson CO (2007) Perspectives on mucosal vaccines: is mucosal tolerance a barrier? J Immunol 179: 5633-5638.
11. Murtaugh MP, Foss DL (2002) Inflammatory cytokines and antigen presenting cell activation. Vet Immunol Immunopathol 87: 109-121.
12. Oyewumi MO, Kumar A, Cui Z (2010) Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. Expert Rev Vaccines 9: 1095-1107.
13. Pavot V, Rochereau N, Genin C, Verrier B, Paul S (2012) New insights in mucosal vaccine development. Vaccine 30: 142-154.
14. Reed LJ, Muench H (1938) A simple method of estimating fifty percent endpoint. Am J Hyg 27: 493-497.
15. Renukuntla J, Vadlapudi AD, Patel A, Boddu SH, Mitra AK (2013) Approaches for enhancing oral bioavailability of peptides and proteins. Int J Pharm 447: 75-93.
16. Shi L, Sanyal G, Ni A, Luo Z, Doshna S, Wang B, Graham TL, Wang N, Volkin DB (2005) Stabilization of human papillomavirus virus-like particles by non-ionic surfactants. J Pharm Sci 94: 1538-1551.
17. Slutter B, Hagenaars N, Jiskoot W (2008) Rational design of nasal vaccines. J Drug Target 16: 1-17.
18. Thomas DS (1988) Electropositively charged filters for the recovery of yeasts and bacteria from beverages. J Appl Bacteriol 65: 35-41.
19. Thones N, Herreiner A, Schadlich L, Piuko K, Muller M (2008) A direct comparison of human papillomavirus type 16 L1 particles reveals a lower immunogenicity of capsomeres than virus like particles with respect to the induced antibody response. J Virol 82: 5472-5485.
20. Tuthill TJ, Harlos K, Walter TS, Knowles NJ, Groppelli E, Rowlands DJ, Stuart DI, Fry EE (2009) Equine rhinitis A virus and its low pH empty particle: clues towards an aphthovirus entry mechanism? PLoS Pathog 5: e1000620.
21. van de Graaff KM (1986) Anatomy and physiology of the gastrointestinal tract. Pediatr Infect Dis 5: S11-S16.
22. van Zutphen T, Baerends RJ, Susanna KA, de Jong A, Kuipers OP, Veenhuis M, van der Klei IJ (2010) Adaptation of Hansenula polymorpha to methanol: a transcriptome analysis. BMC Genomics 11: 1.
23. Xiang SD, Scholzen A, Minigo G, David C, Apostolopoulos V, Mottram PL, Plebanski M (2006) Pathogen recognition and development of particulate vaccines: does size matter? Methods 40: 1-9.
24. Xu ML, Kim HJ, Choi YR, Kim HJ (2012) Intake of Korean red ginseng extract and saponin enhances the protection conferred by vaccination with inactivated influenza A virus. J Ginseng Res 36: 396-402.
25. Zhang H, Huang Y, Fayad R, Spear GT, Qiao L (2004) Induction of mucosal and systemic neutralizing antibodies against human immunodeficiency virus type 1 (HIV-1) by oral immunization with bovine Papillomavirus-HIV-1 gp41 chimeric virus-like particles. J Virol 78: 8342-8348.